MYOV Myovant Sciences Ltd.

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction and is under phase 2 clinical trial. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.

Date	Price Target	Rating	Analyst
10/26/2022		Outperform → In-line	Evercore ISI
8/9/2022	$12.00 → $23.00	Mkt Perform → Outperform	SVB Leerink
2/16/2022	$21.00 → $19.00	Market Perform	SVB Leerink
1/5/2022	$23.00 → $21.00	Market Perform	SVB Leerink
10/27/2021	$24.00 → $23.00	Market Perform	SVB Leerink
9/9/2021	$24.00	Market Perform	SVB Leerink
8/20/2021	$18.00	Neutral	Goldman

Myovant Sciences Ltd.

Peers

Recent Analyst Ratings for Myovant Sciences Ltd.

Myovant Sciences Ltd. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4: Valente Nancy returned 3,673 shares to the company, closing all direct ownership in the company (withholding obligation)

SEC Form 4: Potter Myrtle S returned 3,673 shares to the company, closing all direct ownership in the company to satisfy tax liability

SEC Form 4: Merendino Lauren returned 169,538 shares to the company, closing all direct ownership in the company to satisfy withholding tax

SEC Form 4: Mehra Uneek returned 202,696 shares to the company, closing all direct ownership in the company (for tax liability)

SEC Form 4: Marek David C returned 417,599 shares to the company, closing all direct ownership in the company to satisfy withholding tax

SEC Form 4: Lang Matthew returned 354,303 shares to the company, closing all direct ownership in the company (for withholding tax)

SEC Form 4: Gulfo Adele M. returned 3,673 shares to the company, closing all direct ownership in the company to satisfy withholding obligation

SEC Form 4: Guinan Mark returned 3,673 shares to the company, closing all direct ownership in the company to satisfy tax liability

SEC Form 4: Curran Terrie returned 3,673 shares to the company, closing all direct ownership in the company to satisfy withholding obligation

SEC Form 4: Arjona Ferreira Juan Camilo returned 246,684 shares to the company, closing all direct ownership in the company to satisfy withholding obligation